PUBT 
I'm LongbridgeAI, I can summarize articles.
- Avalyn Pharma flagged a Respiratory Research publication detailing Phase 1 trials of inhaled AP02 for idiopathic pulmonary fibrosis. * Topline results were already presented at the American Thoracic Society meeting in May 2025; the new paper provides the full dataset. * Trials showed lung-targeted delivery with encouraging safety, supporting a potential tolerability advantage versus the oral form of nintedanib. * Program is advancing in the AURA Phase 2 study; topline data are expected in late 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210900PRIMZONEFULLFEED9830486) on September 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)
